10 Years of progress for patients
24 June 2025
Pharmablue
Expanding Access, Transforming Lives
Since 2015, PharmaBlue has worked alongside innovative pharmaceutical companies so that patients with unmet medical needs can receive timely access to transformative therapies.
Through our Exploitant services and expertise in Early Access Programs, we’ve helped bring life-changing treatments to more than 10,000 patients in France.
These are patients who often have no other therapeutic options—those living with rare, severe, or life-threatening conditions. When a treatment is ready, our role is to help it reach them sooner.
The urgency of unmet medical needs
Whether due to rare conditions, high costs, or regulatory delays, unmet medical needs remain a critical challenge in global healthcare.
- In Europe, 1 in 5 patients report difficulty accessing the medicines they need.*
- Many rare and complex diseases still have no approved therapies.**
- Early Access Programs are often the only route to treatment for these patients.
- In France, Early Access Programs and Compassionate Access Programs frameworks are vital tools for bridging this gap.
PharmaBlue is proud to be part of the solution—helping our clients navigate these challenges and deliver hope to those who need it most.
Looking Ahead to 2035
As we enter our second decade, our vision is clear: to expand access to a broader range of safe, effective healthcare solutions—supporting our partners in delivering cutting-edge treatments to more patients, more efficiently.
We remain focused on what matters most: patients, partnerships, and progress.
Sources:
Did you like this article? Share on social networks:
